

Basic information	
<b>2000/0132(COD)</b> COD - Ordinary legislative procedure (ex-codecision procedure) Directive	Procedure completed
Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists  Amending Directive 96/22/EC 1993/1036(CNS)  <b>Subject</b>  3.10.08 Animal health requirements, veterinary legislation and pharmacy 4.60.04.04 Food safety	

Key players				
European Parliament	<b>Committee responsible</b>		<b>Rapporteur</b>	<b>Appointed</b>
	<b>ENVI</b> Environment, Public Health, Consumer Policy		OLSSON Karl Erik (ELDR)	12/07/2000
	<b>Former committee responsible</b>		<b>Former rapporteur</b>	<b>Appointed</b>
	<b>ENVI</b> Environment, Public Health, Consumer Policy		OLSSON Karl Erik (ELDR)	12/07/2000
	<b>Former committee for opinion</b>		<b>Former rapporteur for opinion</b>	<b>Appointed</b>
	<b>ITRE</b> Industry, External Trade, Research, Energy		PIÉTRASANTA Yves (V /ALE)	13/09/2000
	<b>AGRI</b> Agriculture and Rural Development		MÜLLER Emilia Franziska (PPE-DE)	11/07/2000
Council of the European Union	<b>Council configuration</b>		<b>Meetings</b>	<b>Date</b>
	Agriculture and Fisheries		2524	2003-07-22
	Agriculture and Fisheries		2486	2003-02-20
	Agriculture and Fisheries		2476	2002-12-16
European Commission	<b>Commission DG</b>		<b>Commissioner</b>	
	Health and Food Safety			

Key events			
Date	Event	Reference	Summary
24/05/2000	Legislative proposal published	COM(2000)0320 	<a href="#">Summary</a>
07/07/2000	Committee referral announced in Parliament, 1st reading		
09/01/2001	Vote in committee, 1st reading		<a href="#">Summary</a>
09/01/2001	Committee report tabled for plenary, 1st reading	<a href="#">A5-0002/2001</a>	
01/02/2001	Decision by Parliament, 1st reading	<a href="#">T5-0051/2001</a>	<a href="#">Summary</a>
01/02/2001	Debate in Parliament		
06/03/2001	Modified legislative proposal published	COM(2001)0131 	<a href="#">Summary</a>
20/02/2003	Council position published	<a href="#">14502/1/2002</a>	<a href="#">Summary</a>
13/03/2003	Committee referral announced in Parliament, 2nd reading		
22/05/2003	Vote in committee, 2nd reading		<a href="#">Summary</a>
22/05/2003	Committee recommendation tabled for plenary, 2nd reading	<a href="#">A5-0201/2003</a>	
01/07/2003	Debate in Parliament		
02/07/2003	Decision by Parliament, 2nd reading	<a href="#">T5-0317/2003</a>	<a href="#">Summary</a>
22/07/2003	Act approved by Council, 2nd reading		
22/09/2003	Final act signed		
22/09/2003	End of procedure in Parliament		
14/10/2003	Final act published in Official Journal		

Technical information	
Procedure reference	2000/0132(COD)
Procedure type	COD - Ordinary legislative procedure (ex-codecision procedure)
Procedure subtype	Legislation
Legislative instrument	Directive
Amendments and repeals	Amending Directive 96/22/EC <a href="#">1993/1036(CNS)</a>
Legal basis	EC Treaty (after Amsterdam) EC 152-p4
Stage reached in procedure	Procedure completed
Committee dossier	ENVI/5/14406

Documentation gateway				
European Parliament				
Document type	Committee	Reference	Date	Summary

Committee report tabled for plenary, 1st reading/single reading		<a href="#">A5-0002/2001</a>	09/01/2001	
Text adopted by Parliament, 1st reading/single reading		<a href="#">T5-0051/2001</a> <a href="#">OJ C 267 21.09.2001, p. 0020-0053</a>	01/02/2001	<a href="#">Summary</a>
Committee recommendation tabled for plenary, 2nd reading		<a href="#">A5-0201/2003</a>	22/05/2003	
Text adopted by Parliament, 2nd reading		<a href="#">T5-0317/2003</a> <a href="#">OJ C 074 24.03.2004, p. 0100-0625 E</a>	02/07/2003	<a href="#">Summary</a>

#### Council of the EU

Document type	Reference	Date	Summary
Council statement on its position	<a href="#">05193/2003</a>	06/02/2003	
Council position	<a href="#">14502/1/2002</a> <a href="#">OJ C 090 15.04.2003, p. 0001-0008 E</a>	20/02/2003	<a href="#">Summary</a>

#### European Commission

Document type	Reference	Date	Summary
Legislative proposal	<a href="#">COM(2000)0320</a>  <a href="#">OJ C 337 28.11.2000, p. 0163 E</a>	24/05/2000	<a href="#">Summary</a>
Modified legislative proposal	<a href="#">COM(2001)0131</a>  <a href="#">OJ C 180 26.06.2001, p. 0190 E</a>	06/03/2001	<a href="#">Summary</a>
Commission communication on Council's position	<a href="#">SEC(2003)0285</a> 	07/03/2003	<a href="#">Summary</a>
Commission opinion on Parliament's position at 2nd reading	<a href="#">COM(2003)0489</a> 	11/08/2003	<a href="#">Summary</a>

#### Other institutions and bodies

Institution/body	Document type	Reference	Date	Summary
EESC	Economic and Social Committee: opinion, report	<a href="#">CES1213/2000</a> <a href="#">OJ C 014 16.01.2001, p. 0047</a>	19/10/2000	

#### Additional information

Source	Document	Date
European Commission	<a href="#">EUR-Lex</a>	

#### Final act

--

## Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists

2000/0132(COD) - 07/03/2003 - Commission communication on Council's position

The Commission supports the common position adopted by the Council as the best compromise that could be reached and has made a relevant declaration during the Council of Agriculture of 16 December 2002. The Council and the Commission emphasise that the aim pursued in Article 11a is to ban in five years' time the use of oestradiol 17 beta and its ester-like derivatives for treating farm animals and replace it with equally effective substances.

## Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists

2000/0132(COD) - 20/02/2003 - Council position

The common position, adopted with the abstention of the United Kingdom, is based on a modified Commission proposal that already includes several amendments proposed by then European Parliament into account. As adopted by the Council by qualified majority, it does not alter the basic objectives of the proposed Directive: to protect consumer health and reach WTO compliance. There is no difference of opinion between the Council, the European Parliament and the Commission regarding the essential elements of the proposed directive and in particular on the need for maintaining a prohibition on the use of oestradiol 17 beta and its ester-like derivatives for growth promotion purposes and to introduce a temporary precautionary prohibition on the use of other hormones while additional scientific information, necessary for a fuller assessment of the risk, is gathered. In deciding such measures the Council has taken into account the latest scientific evidence and risk assessments, in particular the opinion of the SCVMPH of April 2002, together with other possible consequences, in particular environmental, of the large scale use of hormones in stock farming. The recitals of the proposed directive have been modified accordingly. Contrary to the Commission's proposal, the Council considered preferable to let the Parliament and the Council take future risk management decisions concerning the updates of the directive's provisions in the light of the new evidence which the Commission is required to gather taking into account recent scientific data from all possible sources and present to them. The Council, in agreement with the Commission and Parliament, has decided to maintain the use of certain of the substances, where this is strictly necessary, for therapeutic purposes or zootechnical treatment as this is not likely to constitute an unacceptable hazard for public health due to the nature and the limited duration of the treatments, the limited quantities administered and the strict conditions under which their administration can take place, laid down in Directive 96/22/EC in order to prevent any possible misuse. The Council has, however, considered appropriate, in the light of the existing information to limit as far as reasonably achievable the exposure to oestradiol 17 beta and only authorise those very few treatments (foetus maceration or mummification, pyometra in cattle and oestrus induction in cattle, horses, sheep or goats) for which no viable and effective alternatives seem presently to be available. Such treatments are not likely to present an unacceptable risk to public health, especially in the light of the new very stringent conditions required to be taken to avoid any possible abusive use. The Council has equally provided for a timely review of the provisions concerning treatments of farm animals with oestradiol 17 beta. Lastly, the Council feels that the fact that it has to a very large extent taken account of the European Parliament's position ought to lead to an early adoption of the Directive. There are also some statements added to this text, such as : - the Council and the Commission emphasise that the aim pursued in Article 11a is, in five years' time, to ban the use of oestradiol 17 beta or its ester-like derivatives for treating farm animals and replace it with equally effective substances; - the Commission undertakes to continue its efforts to establish Community-wide harmonised maximum levels for natural sex hormones and validated methods of analysis, having due regard to physiological levels observed in farm animals.

## Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists

2000/0132(COD) - 24/05/2000 - Legislative proposal

PURPOSE : to amend Council directive 96/22/EC regarding the use in stockfarming of certain hormonal substances. CONTENT : in the light of an opinion of the Scientific Committee on Veterinary measures relating to Public Health (SCVPH), the Commission proposes definitively to ban the use of oestradiol 17 beta and its ester-like derivatives in farm animals and to only allow its administration to non-farm animals for therapeutic purposes. The administration of five other hormonal substances for animal growth promotion purposes is prohibited by the above directive. These are testosterone, progesterone, trenbolone acetate, zeranol and melengestrol acetate. In the case of these five, the need for further information has been identified. Therefore, the Commission proposes to continue provisionally to apply the prohibition on these five hormones until more complete scientific information is made available. The use of some of these substances may, however, continue to be authorised for therapeutic purposes and zootechnical treatment under the conditions of Council directive 96/22/EC. In comparison to the present situation, this proposal has an impact on imports from third countries who legally use oestradiol 17 beta and its ester-like derivatives for therapeutic purposes or zootechnical treatment in farm animals. The Commission considers the presentation of this proposal represents another step towards the implementation of the European Community's international obligations, specifically in the World Trade Organisation.

## **Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists**

2000/0132(COD) - 11/08/2003 - Commission opinion on Parliament's position at 2nd reading

The Commission supports the compromise proposal presented at the EP Plenary on 1 July 2003 as it meets the main objectives (to protect consumer health and to reach compliance with the requirements of the World Trade Organisation).

## **Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists**

2000/0132(COD) - 02/07/2003 - Text adopted by Parliament, 2nd reading

The European Parliament adopted some of the amendments in the report by Karl Erik OLSSON (ELDR, Sweden). The amendments were designed to phase out the use of oestradiol 17 for oestrus induction over three years. However, the use of oestradiol for the treatment of certain conditions (foetus maceration or mummification or pyometra in cattle) is maintained under strict conditions.

## **Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists**

2000/0132(COD) - 01/02/2001 - Text adopted by Parliament, 1st reading/single reading

The European Parliament adopted the report by Mr Karl Erik Olsson (ELDR, S). Several amendments were adopted, one of which is designed to strengthen the monitoring of imports from third countries. (Please refer to the previous text).

## **Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists**

2000/0132(COD) - 22/09/2003 - Final act

PURPOSE : to prohibit certain substances in stock farming. LEGISLATIVE ACT : Directive 2003/74/EC of the European Parliament and of the Council amending Council Directive 96/22/EC concerning the prohibition on the use in stock farming of certain substances having a hormonal or thyrostatic action and of beta-agonists. CONTENT : Directive 96/22/EC requires Member States to prohibit the administration to farm animals of substances having an oestrogenic, androgenic or gestagenic action. Nevertheless administration of those substances to farm animals may be authorised but only if they are used for therapeutic purposes or zootechnical treatment, in accordance with the Directive. Directive 96/22/EC also requires Member States to prohibit the importation from third countries of farm animals to which the substances have been administered, except in certain specified circumstances. In the light of the results of a dispute settlement case brought before the World Trade Organisation (WTO) by the United States of America and by Canada (the Hormones case) and recommendations made in that respect by the WTO Dispute Settlement Body on 13 February 1998, the Commission immediately initiated a complementary risk assessment of the six hormonal substances (oestradiol 17 beta, testosterone, progesterone, trenbolone acetate, zeranol and melengestrol acetate) whose administration for animal growth promotion purposes is prohibited by Directive 96/22/EC. The conclusions of the Scientific Committee on Veterinary Measures relating to Public Health (SCVPH) indicate that a risk to the consumer has been identified with different levels of conclusive evidence for the six hormones evaluated. Furthermore, for the six hormones endocrine, developmental, immunological, neurobiological, immunotoxic, genotoxic and carcinogenic effects could be envisaged. Prepubertal children constitute the group of greatest concern. Finally, no threshold levels and, therefore, no acceptable daily intake (ADI) can be established for any of the six hormones evaluated when they are administered to bovine animals for growth promotion purposes. - With regard to the use of oestradiol 17 beta, a substantial body of recent evidence suggests that it has to be considered as a complete carcinogen, as it exerts both tumour-initiating and tumour-promoting effects. It can potentially be used in all farm animals and residue intake for all segments of the human population. The avoidance of such intake is of absolute importance to safeguard human health. Furthermore, the routine use of the above substances for animal growth promotion purposes is likely to lead to increased concentration of those substances in the environment. - As regards the other five hormones (testosterone, progesterone, trenbolone acetate, zeranol and melengestrol acetate), the SCVPH assessment is that the current state of knowledge does not make it possible to give a quantitative estimate of the risk to consumers. This Directive therefore maintains the permanent prohibition laid down in Directive 96/22/EC on oestradiol 17 beta and continues provisionally to apply the prohibition to the other five hormones. However, the use of certain of these substances for therapeutic purposes or zootechnical treatment may continue to be authorised as it is not likely to constitute a hazard for public health owing to the nature and the limited duration of the treatments. The exposure to oestradiol 17 beta is limited to those treatments for which no viable effective alternatives exist. In general, there are alternative treatments or strategies available to replace most of the uses of oestradiol 17 beta for therapeutic or zootechnical purposes. Nonetheless, studies appear to show that at present no viable effective alternatives exist in all the Member States for certain treatments which are currently authorised. In order to allow for the necessary adjustments and in particular for the authorisation or the mutual recognition of the pharmaceutical products needed, the Directive phases out the use of oestradiol 17 beta for oestrus induction over three years (until 14/10/06.) The Directive also maintains the possibility of authorising its use for the treatment of foetus maceration or mummification and pyometra in cattle which have serious consequences for animal health and welfare. The Commission must present a review of this by 14/10/05. DATE FOR TRANSPOSITION : 14/10/04. ENTRY INTO FORCE : 14/10/03.

# **Stockfarming: prohibition of certain substances with hormonal or thyrostatic action, of beta-agonists**

2000/0132(COD) - 06/03/2001 - Modified legislative proposal

The amended proposal includes clarifications proposed by the European Parliament as regards wording in Article 1 (4) and Article 1 (7), in particular to the effect that the Commission will take into account recent scientific data from any source when keeping the measures under review.